Vol. 6 No. 3 (2026)
Reimbursement Reviews

Efgartigimod Alfa Injection (Vyvgart SC)

decorative image of the issue cover

Published March 13, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses efgartigimod alfa injection (Vyvgart SC), 1,000 mg/5 mL (200 mg/mL) solution in single-dose prefilled syringe for SC use.
  • Indication: As a monotherapy for adult patients with active chronic inflammatory demyelinating polyneuropathy.